J.P. Morgan is out with its report today on Amicus Therapeutics FOLD, maintaining Neutral.
In a note to clients, J.P. Morgan writes, "We are Neutral on FOLD shares. Amicus' chaperone technology is a unique platform in biotech that could offer treatment for a wide range of diseases, including Fabry disease and Parkinson's disease. Longer term we think there is a good probability that Amigal for Fabry disease will be successful, and we expect other earlier stage compounds to move forward. However, we think the announcement that Plicera failed a phase 2 study in Gaucher disease was a negative announcement that may increase the discount on Amicus' technology until data from other programs are made available."
At the time of posting, shares of FOLD were trading at $7.26, up 0.69% from Monday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in